FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer

AI summary

The U.S. FDA has approved a first-in-class targeted therapy for metastatic pancreatic cancer, marking a new treatment option for a disease with limited effective therapies. The approval is notable as a regulatory milestone in oncology and could expand access for patients whose tumors match the therapy’s target.